Prosecution Insights
Last updated: November 20, 2026
Application No. 17/887,175

Apparatus for Treating Knee Abnormalities

Final Rejection §DOUBLEPATENT
Filed
Aug 12, 2022
Priority
Mar 03, 2017 — continuation of 11/123,253 +1 more
Examiner
MOON, MATTHEW RYAN
Art Unit
3785
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Ergo-Flex Technologies LLC
OA Round
2 (Final)
58%
Grant Probability
Moderate
3-4
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 58% of resolved cases
58%
Career Allowance Rate
200 granted / 343 resolved
-11.7% vs TC avg
Strong +60% interview lift
Without
With
+60.5%
Interview Lift
resolved cases with interview
Typical timeline
3y 2m
Avg Prosecution
46 currently pending
Career history
397
Total Applications
across all art units

Statute-Specific Performance

§101
2.8%
-37.2% vs TC avg
§103
44.5%
+4.5% vs TC avg
§102
16.8%
-23.2% vs TC avg
§112
29.8%
-10.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 343 resolved cases

Office Action

§DOUBLEPATENT
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Response to Amendment This Office Action is in response to an amendment filed on 9/8/2026. As directed by the amendment, claims 11-20 were canceled, and no claims were amended or added. Thus, claims 1-10 are pending for this application. Terminal Disclaimer The terminal disclaimer filed on 9/8/2026 disclaiming the terminal portion of any patent granted on this application which would extend beyond the expiration date of US Patent Nos. 11,123,253; 11,426,007; and 7,654,974 has been reviewed and is Disapproved for the following reasons: The terminal disclaimer filed 9/8/2026 was not signed and the printed name and registration number for the signing attorney is missing. See Terminal Disclaimer review decision dated 9/17/2026 for more details. US Patent Nos. 11,426,007 and 7,654,974 do not appear to belong to applicant and thus should be removed from the Terminal Disclaimer. Examiner attempted to contact applicant’s representative multiple times to have this issue corrected but was unable to reach applicant’s representative. Drawings The drawings are objected to because: Figures 8-13 of the replacement drawings filed 10/12/2022 are objected to because the unlabeled rectangular/ovular/triangular boxes (i.e. 203-204 in Fig. 8, 211-214 in Fig. 9, etc.) should be provided with descriptive text (e.g. unlabeled rectangular box 203 should be provided with “actuator returned to a first, minimum, or home position” inside the box or adjacent to the reference number, as discussed in paragraph [0069]). See 37 CFR 1.83(a). Corrected drawing sheets in compliance with 37 CFR 1.121(d) are required in reply to the Office action to avoid abandonment of the application. Any amended replacement drawing sheet should include all of the figures appearing on the immediate prior version of the sheet, even if only one figure is being amended. The figure or figure number of an amended drawing should not be labeled as “amended.” If a drawing figure is to be canceled, the appropriate figure must be removed from the replacement sheet, and where necessary, the remaining figures must be renumbered and appropriate changes made to the brief description of the several views of the drawings for consistency. Additional replacement sheets may be necessary to show the renumbering of the remaining figures. Each drawing sheet submitted after the filing date of an application must be labeled in the top margin as either “Replacement Sheet” or “New Sheet” pursuant to 37 CFR 1.121(d). If the changes are not accepted by the examiner, the applicant will be notified and informed of any required corrective action in the next Office action. The objection to the drawings will not be held in abeyance. Claim Interpretation The following is a quotation of 35 U.S.C. 112(f): (f) Element in Claim for a Combination. – An element in a claim for a combination may be expressed as a means or step for performing a specified function without the recital of structure, material, or acts in support thereof, and such claim shall be construed to cover the corresponding structure, material, or acts described in the specification and equivalents thereof. The following is a quotation of pre-AIA 35 U.S.C. 112, sixth paragraph: An element in a claim for a combination may be expressed as a means or step for performing a specified function without the recital of structure, material, or acts in support thereof, and such claim shall be construed to cover the corresponding structure, material, or acts described in the specification and equivalents thereof. The claims in this application are given their broadest reasonable interpretation using the plain meaning of the claim language in light of the specification as it would be understood by one of ordinary skill in the art. The broadest reasonable interpretation of a claim element (also commonly referred to as a claim limitation) is limited by the description in the specification when 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, is invoked. As explained in MPEP § 2181, subsection I, claim limitations that meet the following three-prong test will be interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph: (A) the claim limitation uses the term “means” or “step” or a term used as a substitute for “means” that is a generic placeholder (also called a nonce term or a non-structural term having no specific structural meaning) for performing the claimed function; (B) the term “means” or “step” or the generic placeholder is modified by functional language, typically, but not always linked by the transition word “for” (e.g., “means for”) or another linking word or phrase, such as “configured to” or “so that”; and (C) the term “means” or “step” or the generic placeholder is not modified by sufficient structure, material, or acts for performing the claimed function. Use of the word “means” (or “step”) in a claim with functional language creates a rebuttable presumption that the claim limitation is to be treated in accordance with 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph. The presumption that the claim limitation is interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, is rebutted when the claim limitation recites sufficient structure, material, or acts to entirely perform the recited function. Absence of the word “means” (or “step”) in a claim creates a rebuttable presumption that the claim limitation is not to be treated in accordance with 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph. The presumption that the claim limitation is not interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, is rebutted when the claim limitation recites function without reciting sufficient structure, material or acts to entirely perform the recited function. Claim limitations in this application that use the word “means” (or “step”) are being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, except as otherwise indicated in an Office action. Conversely, claim limitations in this application that do not use the word “means” (or “step”) are not being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, except as otherwise indicated in an Office action. This application includes one or more claim limitations that use the word “means” and are being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, because the claim limitation(s) uses a generic placeholder that is coupled with functional language without reciting sufficient structure to perform the recited function and the generic placeholder is not preceded by a structural modifier. Such claim limitation(s) is/are: “means for securing an upper portion of the patient's leg above the knee to the seating surface” in claim 1 lines 4-5 “means for securing a lower portion of the patient's leg below the knee to the support platform, wherein the means for securing the lower portion of the patient's leg is axially movable relative to the support platform” in claim 1 lines 7-9 “means for applying a tension force to the support platform whereby a tension force is applied to the knee joint for causing the knee to be stretched in an axial direction and adjacent bone surfaces of the knee to move away from each other” in claim 1 lines 10-12 Because this/these claim limitation(s) is/are being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, it/they is/are being interpreted to cover the corresponding structure described in the specification as performing the claimed function, and equivalents thereof. In this case, the corresponding structures of “means for securing an upper portion of the patient's leg above the knee to the seating surface” described in paragraph [0054] of the specification include: a strap having hooks and loop fasteners; the corresponding structures of “means for securing a lower portion of the patient's leg below the knee to the support platform, wherein the means for securing the lower portion of the patient's leg is axially movable relative to the support platform” described in paragraph [0054] of the specification include: : a strap having hooks and loop fasteners; and the corresponding structures of “means for applying a tension force to the support platform whereby a tension force is applied to the knee joint for causing the knee to be stretched in an axial direction and adjacent bone surfaces of the knee to move away from each other” described in paragraph [0056] of the specification include: a linear actuator. If applicant does not intend to have this/these limitation(s) interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, applicant may: (1) amend the claim limitation(s) to avoid it/them being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph (e.g., by reciting sufficient structure to perform the claimed function); or (2) present a sufficient showing that the claim limitation(s) recite(s) sufficient structure to perform the claimed function so as to avoid it/them being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 1-4 are rejected on the ground of nonstatutory double patenting as being unpatentable over claim 1 of U.S. Patent No. 11,123,253 in view of Diallo (US 2014/0094721). Although the claims are not identical, they are not patentably distinct from one another. The application claims recite additional features not claimed in the patent claims. For claim 1: Patent claim 1 Application claim 1 Apparatus for treating abnormalities in the knee comprising; a) a chair forming a seating surface for a patient, the chair having a lower laterally extending rod, b) means for securing an upper portion of the patient's leg above the knee to the seating surface, c) a support platform movable with respect to the seating surface, d) means for securing a lower portion of the patient's leg below the knee to the support platform, wherein the means for securing the lower portion of the patient's leg is axially movable relative to the support platform, e) means for applying a tension force to the support platform whereby a tension force is applied to the knee joint for causing the knee to be stretched in an axial direction and adjacent bone surfaces of the knee to move away from each other, and f) a main housing for supporting the support platform, the main housing being axially fixed to the seating surface during operation and the main housing being laterally adjustable along the seating surface via a tubular bearing that is slideably mounted on the rod of the chair; wherein the main housing includes side tracks extending along the axial direction and the main housing including a bottom surface having includes rollers, the side tracks and rollers being used to axially adjust the main housing with respect to the seating surface. An apparatus for treating knee abnormalities, comprising: a chair forming a seating surface for a patient, the chair having a lower laterally extending rod; means for securing an upper portion of the patient's leg above the knee to the seating surface; a support platform movable with respect to the seating surface; means for securing a lower portion of the patient's leg below the knee to the support platform, wherein the means for securing the lower portion of the patient's leg is axially movable relative to the support platform; means for applying a tension force to the support platform whereby a tension force is applied to the knee joint for causing the knee to be stretched in an axial direction and adjacent bone surfaces of the knee to move away from each other; a main housing for supporting the support platform, the main housing being axially fixed to the seating surface during operation and the main housing being laterally adjustable along the seating surface via a tubular bearing that is slideably mounted on the rod of the chair, wherein the main housing includes side tracks extending along the axial direction and the main housing including a bottom surface having rollers, the side tracks and the rollers having a capability to axially adjust the main housing with respect to the seating surface; and a controller system, said controller system for providing control of the means for applying the tension force. With respect to the additional features recited in application claim 1, patent claim 1 fails to recite a controller system, said controller system for providing control of the means for applying the tension force. However, Diallo teaches (Figs. 2, 6, 8 and 11) an apparatus for treating knee abnormalities (the device treats users with knee abnormalities and injuries, see paras. [0008]-[0011]), comprising a controller system (comprising controller 36, power supply 34, user interface 38, remote controller i.e. smart phone, and sensors such as force sensor and strain gauge, see paragraphs [0045], [0046] and [0069]), said controller system for providing control of the means for applying the tension force (paragraph [0046]). Therefore, it would have been obvious to one having ordinary skill in the art at the time the invention was made to modify the apparatus of claim 1 of patent ‘253 to include a controller system, said controller system for providing control of the means for applying the tension force, as taught by Diallo, for the purpose of allowing for user to adjust the device operation according to the treatment prescribed to a user, thereby improving therapeutic outcome. Regarding claim 2, modified claim 1 of patent ‘253 discloses wherein the controller system comprises a power supply (power supply 34 of Diallo) and a microcontroller (controller 36 of Diallo). Regarding claim 3, modified claim 1 of patent ‘253 discloses wherein the controller system is operated wirelessly from a mobile application (app on smart phone, paragraph [0069] Diallo), said mobile application operating on a mobile device (smart phone, paragraph [0069] Diallo), said mobile device comprising any device capable of mobility on which the mobile application may be installed (smart phone, paragraph [0069] Diallo). Regarding claim 4, modified claim 1 of patent ‘253 discloses wherein the controller system communicates with the mobile device via a wireless networking medium (Bluetooth technology, paragraph [0069] Diallo). Claim 5 is rejected on the ground of nonstatutory double patenting as being unpatentable over claim 1 of U.S. Patent No. 11,123,253 in view of Diallo (US 2014/0094721), and further in view of Ruggiero (US 2021/0275388). Regarding claim 5, the modified claim 1 of U.S. Patent No. 11,123,253 discloses an apparatus for providing therapy to a user comprising a controller assembly and mobile application (paragraph [0069] Diallo), but does not disclose wherein the mobile application communicates with a web-based portal via a network communications medium, said web-based portal comprising a user interface, a database, or combinations thereof. However, Ruggiero further discloses (Fig. 4) a mobile application (Fig. 4; “The software application that was downloaded/installed on the mobile communication device”; [0090], Lines 1-2) that communicates with a web-based portal via a network communications medium (Fig. 4; “the mobile communication device can communicate with a remote management system (e.g., management system 408 of FIG. 4) (e.g., a remote sever) over a network (e.g., network 406 of FIG. 4)”; [0090]), said web-based portal (Fig. 4; a remote management system (e.g., management system 408 of FIG. 4, e.g., a remote sever)) comprising a user interface, a database (Fig. 4; datastore 410; [0090]), or combinations thereof. Therefore, it would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify the smartphone implementing the mobile application of the modified claim 1 of U.S. Patent No. 11,123,253 with the network, remote management system, and datastore of Ruggiero to have a remote server that can receive reports of diagnostic information and usage patterns as well as be connected to a datastore which stores registration/account information (Ruggiero: [0061-0062], [0073], [0090], [0104]). Claim 6 is rejected on the ground of nonstatutory double patenting as being unpatentable over claim 1 of U.S. Patent No. 11,123,253 in view of Diallo (US 2014/0094721), and further in view of Jacobs (US 11426007). Regarding claim 6, modified claim 1 of U.S. Patent No. 11,123,253 discloses a controller system having a force sensor and strain gauge to determine tension force (paragraphs [0046] and [0061]), but does not disclose the controller system performs a calibration function to calibrate the tension force applied to the moveable support platform. Jacobs teaches a therapy device comprising a controller system (A remote control may, for example, include fifteen individual buttons: 13 calibrate; Col. 47, Lines 10-22) performs a calibration function to calibrate the tension force applied to the moveable support platform (“After calibration a full extend soft stop may be set such that movement of an associated chairs does not ram into a hard stop. ¼ and ½ open may be set from an associated hard stop”; Col. 47, Lines 10-22) Col. 24, Lines 65-67 and Col. 25, Lines 1-11 and 56-57. Tension force is calibrated indirectly as a result of this calibration by setting hard and soft stops). Therefore it would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify the controller of modified claim 1 of U.S. Patent No. 11,123,253 to have a calibration button as taught in Jacobs to set a full extend soft stop after calibration such that device does not ram into a hard stop (Jacobs: Col. 47, Lines 10-22), thereby preventing injury to a user. Claims 7- 9 are rejected on the ground of nonstatutory double patenting as being unpatentable over claim 1 of U.S. Patent No. 11,123,253 in view of Diallo (US 2014/0094721), and further in view of Bass (US 7,654,974). Regarding claim 7, modified claim 1 of U.S. Patent No. 11,123,253 the means for applying the tension force to the moveable support platform is controlled by one or more protocols performed by the controller system, but does not disclose said one or more protocols comprising a protocol completion function. However, Bass teaches (Fig. 14-18) a therapy device comprising a movable platform (traction device 10) controlled by one or more protocols performed by the controller system (“The doctor can also set the controller's "session treatment time"; Col. 10, Lines 28-29), said one or more protocols (Col. 10, Lines 28-39) comprising a protocol completion function (Col. 10, Lines 28-39). Therefore it would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify the controller of the modified device of modified claim 1 of U.S. Patent No. 11,123,253 to be able to set the controller as taught by Bass in order to have a customizable session treatment time that the actuator will cycle through (Bass: Col. 10, Lines 28-39). Regarding claim 8, modified claim 1 of U.S. Patent No. 11,123,253 discloses wherein the protocol completion function causes the means for applying the tension force to the moveable support platform to pause for a duration of time at a current configuration and then return to a home position. (“After the 12 minutes are timed out, the seat-bottom actuator motor 245 returns to its pre-distraction neutral position and can shut itself off”; Col. 10, Lines 28-39 Bass). Regarding claim 9, modified claim 1 of U.S. Patent No. 11,123,253 discloses wherein the one or more protocols: cause the means for applying the tension force to the support platform to apply all of, or one or more portions of, a prescribed tension force to the support platform (“once the desired distraction force is achieved, the doctor may then set the controller 212 to begin intermittent cycling of the actuator motor 245 and repeat the actuator's movement back and forth”; tolerance (patients tolerance of how far the seat is moved away) of distraction force is set by foot pedal; Col. 10, Lines 18-27 Bass). Regarding claim 10, modified claim 1 of U.S. Patent No. 11,123,253 discloses wherein the one or more protocols comprises a static traction protocol (Diallo discloses controller includes a protocol holds tension until user overcomes, paragraph [0060] Diallo). Allowable Subject Matter Claims 1-10 are allowable over the prior art of record, but is currently rejected under non-statutory double patenting. A terminal disclaimer disclaiming the parent application would overcome rejection. Response to Arguments Applicant’s arguments filed 9/8/2026 have been fully considered. Regarding the objections to drawings, applicant’s amendment to Fig. 7 have been considered and sufficient to overcome objection, and thus previous objections to the drawings for Fig. 7 have been withdrawn. However, objections to Figs. 8-13 have been maintained. Specifically, labeling one of the unlabeled box with “method step” is not sufficient descriptive text for each box. Applicant is suggested to label the boxes with the associated method steps discussed in paragraphs [0069]-[0077] (e.g. unlabeled rectangular box 203 should be provided with “actuator returned to a first, minimum, or home position” inside the box or adjacent to the reference number, as discussed in paragraph [0069]). Applicant’s arguments regarding allowability of claims 1-10 have been considered but are moot because the terminal disclaimer filed was not approved, and thus claims 1-10 are still rejectable due to non-statutory double patenting. Conclusion THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to MATTHEW R MOON whose telephone number is (571)272-2554. The examiner can normally be reached Monday-Thursday 7:30am-5:30pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Timothy Stanis can be reached at 571-272-5139. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MATTHEW R MOON/Examiner, Art Unit 3785 /TIMOTHY A STANIS/Supervisory Patent Examiner, Art Unit 3785
Read full office action

Prosecution Timeline

Aug 12, 2022
Application Filed
Dec 03, 2025
Response after Non-Final Action
Jan 27, 2026
Response Filed
Mar 12, 2026
Non-Final Rejection mailed — §DOUBLEPATENT
Sep 08, 2026
Response Filed
Oct 20, 2026
Final Rejection mailed — §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12802808
METHODS AND SYSTEMS FOR VENTILATORS
4y 12m to grant Granted Nov 17, 2026
Patent 12797568
AIRWAY ADAPTER
3y 1m to grant Granted Nov 17, 2026
Patent 12778833
GRIP THERAPY DEVICES AND REHABILITATION SYSTEMS
4y 1m to grant Granted Nov 03, 2026
Patent 12779163
VENTILATION AND NOISE REDUCTION HOUSING AND ASSEMBLY, VENTILATION AND MOISTURE RETENTION APPARATUS, BREATHING MASK ASSEMBLY, AND BREATHING SUPPORT DEVICE
3y 0m to grant Granted Nov 03, 2026
Patent 12751891
BODY MASSAGE DEVICE
3y 11m to grant Granted Oct 06, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
58%
Grant Probability
99%
With Interview (+60.5%)
3y 2m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 343 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month